

Kent W Mouw

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1408359/kent-w-mouw-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

79
papers

2,534
citations

24
h-index

49
g-index

87
ext. papers

3,475
ext. citations

8.3
avg, IF

5.14
L-index

#	Paper	IF	Citations
79	Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. <i>Cancer Discovery</i> , 2014 , 4, 1140-53	24.4	361
78	DNA Damage and Repair Biomarkers of Immunotherapy Response. <i>Cancer Discovery</i> , 2017 , 7, 675-693	24.4	331
77	A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. <i>Nature Genetics</i> , 2017 , 49, 1476-1486	36.3	255
76	Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. <i>Nature Genetics</i> , 2016 , 48, 600-606	36.3	238
75	Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. <i>Cancer</i> , 2014 , 120, 126-33	6.4	114
74	A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. <i>Cancer Research</i> , 2015 , 75, 628-34	10.1	84
73	Analysis of somatic microsatellite indels identifies driver events in human tumors. <i>Nature Biotechnology</i> , 2017 , 35, 951-959	44.5	72
72	Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2019 , 76, 59-68	10.2	63
71	Shaping the <i>Borrelia burgdorferi</i> genome: crystal structure and binding properties of the DNA-bending protein Hbb. <i>Molecular Microbiology</i> , 2007 , 63, 1319-30	4.1	60
70	Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 977-988	12.9	57
69	Architecture of a serine recombinase-DNA regulatory complex. <i>Molecular Cell</i> , 2008 , 30, 145-55	17.6	53
68	Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. <i>Clinical Cancer Research</i> , 2019 , 25, 2458-2470	12.9	52
67	Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. <i>European Urology</i> , 2018 , 74, 146-154	10.2	50
66	Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. <i>Lancet Oncology</i> , 2018 , 19, e683-e695	21.7	44
65	Molecular Characterization of Neuroendocrine-like Bladder Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 3908-3920	12.9	42
64	Proton radiation therapy for the treatment of retinoblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 90, 863-9	4	36
63	Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017 , 23, 3214-3222	12.9	28

62	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. <i>British Journal of Cancer</i> , 2020 , 122, 555-563	8.7	28
61	Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer. <i>Cancer Research</i> , 2020 , 80, 2094-2100	10.1	28
60	Active Surveillance for Low-Risk Prostate Cancer in Black Patients. <i>New England Journal of Medicine</i> , 2019 , 380, 2070-2072	59.2	26
59	DNA Repair Pathway Alterations in Bladder Cancer. <i>Cancers</i> , 2017 , 9,	6.6	26
58	Regulatory mutations in Sin recombinase support a structure-based model of the synaptosome. <i>Molecular Microbiology</i> , 2009 , 74, 282-98	4.1	26
57	Arginine as a general acid catalyst in serine recombinase-mediated DNA cleavage. <i>Journal of Biological Chemistry</i> , 2013 , 288, 29206-14	5.4	24
56	Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer. <i>Cancer</i> , 2019 , 125, 3164-3171	6.4	23
55	Crosstalk between the nucleotide excision repair and Fanconi anemia/BRCA pathways. <i>DNA Repair</i> , 2014 , 19, 130-4	4.3	23
54	DNA Repair Deficiency and Immunotherapy Response. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1710-1713	2.2	22
53	Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. <i>Cancer Research</i> , 2020 , 80, 4476-4486	10.1	20
52	Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. <i>Genetics in Medicine</i> , 2020 , 22, 709-718	8.1	17
51	Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 Pandemic. <i>JAMA Oncology</i> , 2020 , 6, 1630-1632	13.4	16
50	Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer. <i>JAMA Otolaryngology</i> , 2010 , 136, 1226-34		15
49	EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair. <i>Oncogene</i> , 2020 , 39, 4798-4813	9.2	14
48	Clinical controversies: proton therapy for prostate cancer. <i>Seminars in Radiation Oncology</i> , 2013 , 23, 109-114	5.4	14
47	Sin resolvase catalytic activity and oligomerization state are tightly coupled. <i>Journal of Molecular Biology</i> , 2010 , 404, 16-33	6.5	14
46	Orchestrating serine resolvases. <i>Biochemical Society Transactions</i> , 2010 , 38, 384-7	5.1	14
45	Dosimetric consequences of interobserver variability in delineating the organs at risk in gynecologic interstitial brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 89, 674-81	4	13

44	High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy. <i>Oncologist</i> , 2019 , 24, e275-e283	5.7	12
43	A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. <i>Brachytherapy</i> , 2019 , 18, 186-191	2.4	12
42	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. <i>European Urology</i> , 2019 , 75, 35-41	10.2	12
41	Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 226-234	2.3	12
40	Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. <i>European Urology Oncology</i> , 2020 , 3, 420-423	6.7	11
39	Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. <i>Oral Oncology</i> , 2012 , 48, 1025-1030	4.4	11
38	Nucleotide excision repair (NER) alterations as evolving biomarkers and therapeutic targets in epithelial cancers. <i>Oncoscience</i> , 2015 , 2, 942-3	0.8	11
37	Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer. <i>Cancer</i> , 2017 , 123, 4832-4840	6.4	10
36	Quantification of somatic mutation flow across individual cell division events by lineage sequencing. <i>Genome Research</i> , 2018 , 28, 1901-1918	9.7	10
35	Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 953-959	2.7	9
34	Tumor mutational landscape is a record of the pre-malignant state		8
33	Analysis of patient outcomes following proton radiation therapy for retinoblastoma. <i>Advances in Radiation Oncology</i> , 2017 , 2, 44-52	3.3	7
32	Hypofractionation in the era of modulated radiotherapy (RT). <i>Breast</i> , 2013 , 22 Suppl 2, S129-36	3.6	6
31	Alterations and Response to Immunotherapy in Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 4025-4035	1.5	6
30	Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 2011-2022	12.9	6
29	Applying Precision Oncology Principles in Radiation Oncology. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	6
28	Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 99, 904-911	4	5
27	Impact of a dedicated palliative radiation oncology service on the use of single fraction and hypofractionated radiation therapy among patients with bone metastases. <i>Annals of Palliative Medicine</i> , 2018 , 7, 186-191	1.7	5

26	Assessing the Training and Research Environment for Genomics, Bioinformatics, and Immunology in Radiation Oncology. <i>JCO Clinical Cancer Informatics</i> , 2018 , 2, 1-9	5.2	5
25	Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology.. <i>Nature Cancer</i> , 2021 , 2, 1102-1112	15.4	5
24	Validation of a subclassification for high-risk prostate cancer in a prospective cohort. <i>Cancer</i> , 2020 , 126, 2132-2138	6.4	4
23	Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, 621-627	4	4
22	Functional profiling of nucleotide Excision repair in breast cancer. <i>DNA Repair</i> , 2019 , 82, 102697	4.3	3
21	Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 3734-3743	12.9	3
20	Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques. <i>Radiotherapy and Oncology</i> , 2021 , 161, 241-250	5.3	3
19	Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 246-254.e5	3.3	2
18	Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial. <i>Cancer</i> , 2021 , 127, 2213-2221	6.4	2
17	Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021 , 35, 567-584	3.1	2
16	RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	2
15	Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 108, 936-940	4	1
14	Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 157.e15-157.e20	2.8	1
13	Radiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 ,	4	1
12	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 735.e9-735.e15	2.8	1
11	Three-tiered Subclassification System of High-risk Prostate Cancer in Men Managed With Radical Prostatectomy: Implications for Treatment Decision-making. <i>Urology</i> , 2020 , 145, 197-203	1.6	1
10	Genomic Landscape of Primary and Recurrent Anal Squamous Cell Carcinomas in Relation to HPV Integration, Copy-Number Variation, and DNA Damage Response Genes. <i>Molecular Cancer Research</i> , 2021 , 19, 1308-1321	6.6	1
9	Bladder preservation: Translating discovery for clinical impact in urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 201-208	2.8	1

8	Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	1
7	Clinical characterization of radiation-associated muscle-invasive bladder cancer. <i>Urology</i> , 2021 , 154, 208-214	2.6	1
6	Therapy for Muscle-Invasive Urothelial Carcinoma: Controversies and Dilemmas.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102928	2.2	1
5	Association Between Travel Distance and Use of Postoperative Radiation Therapy Among Men With Organ-Confined Prostate Cancer: Does Geography Influence Treatment Decisions?. <i>Practical Radiation Oncology</i> , 2021 , 11, e426-e433	2.8	0
4	loss overrides PARP inhibitor sensitivity driven by loss in prostate cancer.. <i>Science Advances</i> , 2022 , 8, eabl9794	14.3	0
3	Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 941-948	7.3	
2	Role of Ki-67, MRE11, and PD-L1 as Predictive Biomarkers for Recurrence Pattern in Muscle-invasive Bladder Cancer. <i>Anticancer Research</i> , 2021 , 41, 3851-3857	2.3	
1	Utilization of multimodality therapy with primary radical prostatectomy versus radiation therapy for Gleason 8-10 prostate cancer. <i>Brachytherapy</i> , 2021 , 20, 1-9	2.4	